Zafgen, Inc. (ZFGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZFGN Stock Price Chart Interactive Chart >
ZFGN Price/Volume Stats
|Current price||$11.88||52-week high||$14.88|
|Prev. close||$1.16||52-week low||$0.62|
|Day high||$14.88||Avg. volume||360,199|
|50-day MA||$0.82||Dividend yield||N/A|
|200-day MA||$0.89||Market Cap||445.14M|
Zafgen, Inc. (ZFGN) Company Bio
Zafgen Inc. is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. The company was founded in 2005 and is based in Boston, Massachusetts.
Most Popular Stories View All
ZFGN Latest News Stream
|Loading, please wait...|
ZFGN Latest Social Stream
View Full ZFGN Social Stream
Latest ZFGN News From Around the Web
Below are the latest news stories about Zafgen Inc that investors may wish to consider to help them evaluate ZFGN as an investment opportunity.
Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the completion of its reverse merger with Zafgen, Inc. (ZFGN). The combined, publicly traded clinical-stage biotechnology company will operate under the name Larimar Therapeutics, Inc. and its shares will commence trading on the Nasdaq Global Market on May 29, 2020, under the ticker symbol “LRMR.”
Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein.
A look at some stocks Benjamin Graham might have liked Continue reading...
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 18) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...
Zafgen, Inc. (ZFGN) and Chondrial Therapeutics, Inc., today announced they have entered into a definitive merger agreement under which Chondrial will become a wholly-owned subsidiary of Zafgen and the stockholders of Chondrial Therapeutics will become the majority owners of Zafgen’s outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.
ZFGN Price Returns